760 Saturday, 14 june 2014 Scientific Abstracts relationship between drug administration and change in BMD was found to be not statistically significant (p>0.05). Conclusions: This study suggest that the efficacy of Prolia ® (denosumab), as assessed by BMD measurements at the lumbar spine and femoral neck is not affected by a delay in timing of the subsequent injection. Current best practice is to administer the drug every six months, and although we will continue to strive for this, the preliminary data that we present suggests that there is some flexibility in this timing, especially if a subsequent injection needs to be delayed. A follow-up study with a larger sample size will allow for a more indepth characterization of this relationship. Disclosure of Interest: M. Wong-Pack: None declared, A. Kalani: None declared, J. Hordyk: None declared, G. Ioannidis: None declared, R. Bensen: None declared, W. Bensen: None declared, J. Adachi Grant/research support: Amgen, Speakers bureau: Amgen, Astra Zenica, Eli Lilly, GSK, Merck, Novartis, Nycomed, Pfizer, Proctor and Gamble, Roche, Sanofi-Aventis, Wyeth, BMS, A. Lau Grant/research support: Amgen, Roche, Speakers bureau: Amgen, Roche DOI: 10.1136/annrheumdis-2014-eular.4744 SAT0459 CHARACTERISTICS, TREATMENTS, AND QUALITY OF LIFE OF PATIENTS IN A SWEDISH OSTEOPOROSIS PATIENT REGISTRY A. Krishna 1 , D. Mellström 2 , Z. Li 3 , C.-P.S. Fan 3 , S. Salomonsson 4 , E. Waern 5 . 1 Merck & Co., Inc, Whitehouse Station, United States; 2 Centre for Bone Research at the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; 3 Asclepius Analytics Ltd, Wanchai, Hong Kong; 4 Merck & Co., Inc, Solna; 5 University of Gothenburg, Gothenburg, Sweden Objectives: To describe patient characteristics, use of drug treatments, and quality of life on subjects in a Swedish patient registry database. Methods: A descriptive analysis using a Swedish patient registry collected in an outpatient clinic in the region of Göteborg from 1991 to 2009 (study period). Included subjects were referred to the clinic for DXA scan for bone mineral density (BMD) measurement and osteoporosis (OP) diagnosis. Subjects were invited for a follow-up DXA scan every 2 years if the prior scan showed low BMD/OP diagnosis. This study analyzed patients’ current and previous OP treatments, fracture risk related to characteristics at enrollment, and Quality of life (QoL). QoL was collected post-2004 and measured by EQ-5D-3L covering dimensions of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Current and previous OP treatments were reported among subjects diagnosed with OP at first visit. Means and standard deviation (SD) were reported for continuous measures; percentages were reported for categorical measures. Results: 9,312 subjects were enrolled in the registry, 91% were female, with average age of 64.1 [SD=11.8] years. Average weight and height were 66.1 [SD=20.6] kg and 161.4 [SD=22.3] cm, respectively. 23% of patients reported prior history of fracture > age 40, 35% had family history of fractures, 28% had back pain, and 33% were currently smokers. At the first visit, 35% (3,292) patients had a T-score (either hip or lumbar spine) ≤ -2.5 and 42% (3,897) between -1 and -2.5. 38.5% (3,587) were diagnosed with OP and 43% (4,031) with osteopenia. EQ-5D was available for 1,570 patients whose first visit was post-2004. The average scores were as follow: mobility: 1.37 [SD=0.49], self-care: 1.11 [SD=0.35], usual activities: 1.34 [SD=0.56], pain/discomfort: 1.91 [SD=0.60], and anxiety/depression: 1.52 [SD=0.57]. Among 2,101 diagnosed with OP at first visit and having ≥1 follow-up visit, 55% (1,146) received bisphosphonates (BIS) (alendronate, optinate, and etidronate), 12% (259) received non-BIS (raloxifene and teriparatide), 79% (1,651) received calcium+vitamin D, and 26% (542) received estrogen. Conclusion: This analysis provided an overview of the characteristics in a Swedish registry. In this Swedish population, more than 1/3 of subjects receiving DXA scan were diagnosed with OP or having T-score≤ -2.5; however, approximately one-third received no OP drug treatment (BIS or non-BIS) despite OP diagnosis. Conclusions: The Swedish patient registry presents opportunities to understand various unmet needs among OP patients as a result of extensive information collected overtime. Disclosure of Interest: A. Krishna Employee of: Merck & Co., Inc, D. Mellström Grant/research support: Merck & Co., Inc, Z. Li Consultant for: Merck & Co., Inc, C.-P. S. Fan Consultant for: Merck & Co., Inc, S. Salomonsson Employee of: Merck & Co., Inc, E. Waern Grant/research support: Merck & Co., Inc DOI: 10.1136/annrheumdis-2014-eular.3630 SAT0460 LOW BONE MASS IN PATIENTS WITH SYSTEMIC SCLEROSIS: RELATIONSHIPS WITH DICKKOPF-1 LEVELS AND 25-HYDROXYVITAMIN D STATUS B. Seriolo 1 , R. Brizzolara 1 , S. Soldano 1 , A. Casabella 1 , L. Molfetta 2 , S. Paolino 1 , M.A. Cimmino 1 , G. Botticella 1 , M. Cutolo 1 . 1 Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova; 2 Ortopedic Division, DINOG, University of Genova, Genova, Italy Background: Patients (pts) affected by systemic sclerosis (SSc) show increased risk of bone loss as a result of the chronic inflammatory state, physical inactivity, gut malabsorption or malnutrition, decrease activation of vitamin D in the altered fibrotic skin 1 . Dickkopf-1 (Dkk-1) is recognized as a key regulator of bone remodeling by inhibition of the Wnt signalling required for new bone formation and is increased in postmenopausal pts. Objectives: In this study, bone mineral density (BMD), 25-hydroxyvitamin D [25(OH) D] status and Dkk-1 serum levels were evaluated in order to investigate in SSc pts a possible association between systemic osteoporosis and/or osteopenia, and Dkk-1 concentrations, based on different 25(OH) D status Methods: 64 postmenopausal pts (mean age 63±7 ys) affected by SSc (mean disease duration 6±3 ys) and 43 age-matched healthy controls (mean age 62±5 ys) were evaluated during their regular screenings and after informed consent in different periods of the year. Pts were not treated with vitamin D addiction or bone remodelling drugs. BMD (g/cm 2 ) of the lumbar spine (L 1 -L 4 ) and total hip was analyzed using dual-energy X-ray absorptiometry (DXA) scan (Lunar Prodigy, GE, USA). Dkk-1 serum levels were measured using an enzyme-linked immunosorbent assay and 25(OH)D3 serum levels were evaluated by radioimmunoassay. Vitamin D levels were classified as normal (>30 ng/ml), insufficient (<30 and >10 ng/ml), and deficient <10 ng/ml) Results: 47 of the SSc pts enrolled (73%) presented bone loss, in particular 24 pts (51%) showed osteoporosis and 23 osteopenia. BMD was found significantly lower in the SSc pts than in control group (lumbar spine: 0.990±0.192 g/cm 2 vs 1.039±0.18 g/cm 2 and total hip 0.809±0.125 g/cm 2 vs 0.903±0.11 g/cm 2 , both p<0.001). Dkk-1 levels were significantly higher in SSc pts than in control group (2,702±910 pg/mL vs 2,164±662 pg/mL, p<0.007). Vitamin D levels were found lower in SSc patients than in controls (22.6+ 11 ng/ml vs 49.8+ 10 ng/ml). Interestingly, BMD at lumbar spine and Dkk-1 levels were found, respectively, significantly lower and higher in pts with deficient (n=14) and insufficient (n=30) vitamin D status when compared to pts with normal vitamin D status (lumbar spine 0.868±0.151 g/cm 2 vs 1.077±0.165 g/cm 2 ; total hip 0.662±0.266 g/cm 2 vs 0.788±0.121 g/cm 2 , and Dkk-1 levels 3,258±672 pg/mL and 3,098+586 pg/ml vs 2,033±697 pg/mL, respectively, all p<0.01). Conclusions: This study showed a significant increase in serum levels of Dkk-1, associated with osteopenia/osteoporosis in pts affected by SSc and deficient or insufficient vitamin D status, when compared to healthy postmenopausal subjects. Interestingly, since Dkk-1 blocks activation and proliferation of established myofibroblasts in vitro and blocks pericyte proliferation to PDGF, pericyte migration, gene activation, and cytoskeletal reorganization to TGF-β or connective tissue growth factor (all activated in SSc), its increase observed in SSc pts is matter of further investigations 2 . In addition, Dkk-1 should be considered a further marker of disease activity in SSc patients. References: [1] Cutolo M et al. Autoimmun Rev 2011:12;84-7. [2] Ren S et al. Proc Natl Acad Sci U S A.2013;110:1440-5. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2014-eular.4246 SAT0461 PREVALENCE OF POSTMENOPAUSAL OSTEOPOROSIS IN ALGERIAN WOMEN C. Haouichat , N. Hammoumraoui, S. Lehtihet, H. Djoudi. Rheumatology department, EHS de Douera, Douera, Algiers, Algeria Background: In Algeria, no epidemiological data on postmenopausal osteo- porosis is available which justified this study of prevalence of postmenopausal osteoporosis in our country Objectives: To determine the prevalence of densitometric osteoporosis in postmenopausal women aged 45 and over, living in Douera (Algiers). Look factors to the occurrence of osteoporosis and determine the frequency of fragility fractures Methods: A prospective epidemiological cross-sectional study in which women were selected on the basis of the method of cluster sampling of the first degree in locality of Douera (Algiers) Results: 546 postmenopausal women 45 years and older were included in the study with an average age of 62±9.42 years (range: 45-89 years), personal and family history of documented fractures were found respectively in 21% and 11% of the population Osteoporosis was found in 41.7% (CI: 35% - 48%) of postmenopausal women. The adjusted prevalence of osteoporosis in the Algerian population of women aged 45 years and older was 35.8%. Among the risk factors sought those related to the occurrence of osteoporosis in varied plain analysis and after adjustment, respectively, I’IMC <26 kg/m 2 (OR: 4.32 (1.54 to 12.10) p<0.005), weight <60 kg (OR: 3.28 (1.18 to 9.14) p<0.023), the duration of menopause >15 years (OR: 3.46 (1.41 to 8 50) p<0.007), personal history of fractures (OR: 3.77 (1.58 to 8.9), p<0.003) and the low level of education (OR: 2.34 (1.18 - 4.62) p<0.014). Conclusions: postmenopausal osteoporosis seems common in our study, a number of potential risk factors was determined and who deserves to be validated by a larger study on a representative sample of the Algerian population Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2014-eular.2980